News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Galapagos NV Release: Nanocort(R) Demonstrates Safety and Good Response in Phase I/II Trial
October 27, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MECHELEN, BELGIUM, Oct 27, 2008 (MARKET WIRE via COMTEX) -- Results to be presented today at the 2008 American College of Rheumatology Annual Scientific Meeting in San Francisco, USA
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Europe
MORE ON THIS TOPIC
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
December 15, 2025
·
2 min read
·
Annalee Armstrong
Clinical research
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure
December 12, 2025
·
3 min read
·
Annalee Armstrong
Vaccines
CDC Highlights Efficacy of COVID-19 Shots in Kids Amid FDA Probe of Alleged Deaths
December 12, 2025
·
2 min read
·
Tristan Manalac
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
December 11, 2025
·
1 min read
·
Annalee Armstrong
